HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Gluck, O. Articles by Colice, G. Search for Related Content PubMed PubMed Citation Articles by Gluck, O. Articles by Colice, G.

Recognizing and Treating Glucocorticoid-Induced Osteoporosis in Patients With Pulmonary Diseases^*

^* From the Department of Medicine (Dr. Gluck), University of Arizona College of Medicine, Tucson, AZ; and Pulmonary, Critical Care and Respiratory Services (Dr. Colice), Washington Hospital Center, The George Washington University School of Medicine, Washington, DC.

Correspondence to: Gene Colice, MD, FCCP, Washington Hospital Center, 110 Irving St NW, Washington, DC 20010; e-mail: Gene.Colice{at}Medstar.net

Glucocorticoids are frequently used to treat patients with pulmonary diseases, but continuous long-term use of glucocorticoids may lead to significant bone loss and an increased risk of fragility fractures. Patients with certain lung diseases, regardless of pharmacotherapy—particularly COPD and cystic fibrosis—and patients waiting for lung transplantation are also at increased risk of osteoporosis. Fragility fractures, especially of the hip, will have substantial effects on the health and well-being of older patients. Vertebral collapse and kyphosis secondary to glucocorticoid-induced osteoporosis (GIO) may affect lung function. Identification of patients with osteopenia, osteoporosis, or fragility fractures related to osteoporosis is strongly recommended and should lead to appropriate treatment. Prevention of GIO in patients receiving continuous oral glucocorticoids is also recommended. In patients receiving either high-dose inhaled glucocorticoids or low- to medium-dose inhaled glucocorticoids with frequent courses of oral glucocorticoids, bone mineral density measurements should be performed to screen for osteopenia and osteoporosis. A bisphosphonate (risedronate or alendronate), calcium and vitamin D supplementation, and lifestyle modifications are recommended for the prevention and treatment of GIO.

Key Words: alendronate • bisphosphonate • glucocorticoids • osteoporosis • risedronate

This article has been cited by other articles:

				N. M. Maalouf and E. Shane Osteoporosis after Solid Organ Transplantation J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2456 - 2465. [Abstract] [Full Text] [PDF]

				A. M. Taveira-DaSilva, M. P. Stylianou, C. J. Hedin, O. Hathaway, and J. Moss Bone Mineral Density in Lymphangioleiomyomatosis Am. J. Respir. Crit. Care Med., January 1, 2005; 171(1): 61 - 67. [Abstract] [Full Text] [PDF]

				S. Sethi Musculoskeletal Effects of Chronic Obstructive Pulmonary Disease: Prevalent, Linked, but Ignored Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1267 - 1268. [Full Text] [PDF]

				G. L. Colice Categorizing Asthma Severity: An Overview of National Guidelines Clin. Med. Res., August 1, 2004; 2(3): 155 - 163. [Abstract] [Full Text] [PDF]